BIOGEN INC. (BIIB)

Every figure this model derived for BIIB, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 167,900,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-03-31
cash 4,282,700,000 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-03-31
current assets 9,190,400,000 AssetsCurrent 2026-03-31
current liabilities 2,998,900,000 LiabilitiesCurrent 2026-03-31
equity 18,651,700,000 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 2026-03-31
interest expense 275,100,000 InterestExpense 2026-03-31
ocf 2,590,800,000 NetCashProvidedByUsedInOperatingActivities 2026-03-31
revenue 9,937,400,000 Revenues 2026-03-31
sbc 293,800,000 ShareBasedCompensation 2026-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up BIIB on one particular measure came for.

RatioValue
cash operating margin27.35
current ratio3.06
current ratio reported3.06
deferred revenue growth-53.93
dilution pct0.82
ebit cagr-21.7
ebit yoy-7.38
fcf margin24.38
interest cover5.9
net debt ebitda0.83
operating margin16.33
owner earnings margin21.43
revenue growth1.23
revenue growth per share0.41
roic6.21
rule of 4017.56
sbc pct revenue2.96

What to be careful about

What this model itself distrusts about BIIB's figures. Written by the derivation as it ran, not added afterwards.